



ROME
24-25 May 2019

HOTEL QUIRINALE,
Via Nazionale 7

PROGRAMME



2019:
PRECISION
ONCOLOGY



Associazione Italiana di Oncologia Medica



Associazione Italiana di Oncologia Medica

GENERAL INFORMATIONS



CONGRESS LOCATION

The conference takes place in Rome, at the Hotel Quirinale (Via Nazionale, 7 Tel: 06 4707) on **24 and 25 May 2019**. The Organizing Secretariat is available to participants at the conference venue from 9.00 am on 24 May and for the whole duration of the event.



SUBSCRIPTIONS

Subscription entitles to participation in scientific work, to receiving the folder containing scientific documents, the attendance certificate and the admission to working lunch.



ATTENDANCE CERTIFICATE


The attendance certificate will be given to all participants regularly registered in the course, who will request it at the secretary desk at the end of the work.

ECM



For this course the Commissione Nazionale per la Formazione Continua in Medicina (National Commission for Refresher Courses in Medicine) (ECM) of the Ministry of Health assigns, n. **7.7** training credits for the following professional figures of PHYSICIAN AND SURGEON (oncology, pathological anatomy, pharmacology and clinical toxicology, gynaecology and obstetrics, general surgery, radiation therapy, medical technician of biomedical laboratory, urology, clinical biochemistry, medical genetics), BIOLOGIST and NURSE.

To obtain the ECM credits, it is necessary to participate in at least 90% of the scientific papers, completely fill out the ECM dossier, correctly answer to at least 75% of the questions and return the dossier to the organizational secretariat at the end of the work. Upon completing the training activity, the participant will be given an attendance certificate while the certificate showing the ECM credits will be sent after the completion of the procedure so that the questionnaires can be corrected. Speakers are entitled to 1 credit for every half hour of teaching regardless of the credits assigned to the event.



Roberto Bordonaro

P. O. Garibaldi-Nesima,
Catania

Emilio Bria

Università Cattolica del Sacro Cuore,
Fondazione Policlinico 'A. Gemelli',
Roma

Ettore Capoluongo

U.O.S.D. Fondazione Policlinico
'A. Gemelli', IRCCS,
Roma

Carlo Carnaghi

Humanitas Mater Domini,
Castellanza (VA)

Giacomo Carteni

A. O. Cardarelli,
Napoli

Vanna Chiarion Sileni

Istituto Oncologico Veneto,
Padova

Saverio Cinieri

A.S.L. Brindisi

Francesco Cognetti

I.F.O. Regina Elena IRCCS,
Roma

Pierfranco Conte

Istituto Oncologico Veneto,
Padova

Laura Cortesi

A.O. Policlinico Universitario,
Modena

Romano Danesi

Università degli Studi,
Pisa

Emanuele De Luca

Azienda Ospedaliera- Universitaria
an Luigi Gonzaga,
Orbassano (TO)

Gaetano De Rosa

Università Federico II - Napoli

Angelo Del Monte

Istituto Scientifico Romagnolo per lo
Studio e la Cura dei Tumori (I.R.S.T.),
Meldola (FC)

Marzia Del Re

Ospedale S. Chiara,
Pisa

Massimo Di Maio

A.O. Ordine Mauriziano,
Torino

Alessandra Fabi

I. F. O. Regina Elena,
Roma

Stefania Gori

Presidente Nazionale AIOM,
Direttore Oncologia Medica - IRCCS
Ospedale Sacro Cuore - Don Calabria,
Negrar (VR)

Francesco Grossi

Ist. Naz. Ricerca Cancro,
Genova

Valentina Guarneri

Istituto Oncologico Veneto IRCCS,
Padova

Lorena Incorvaia

A.O.U. Policlinico "Paolo Giaccone",
Palermo

Alessandro Inno

IRCCS Ospedale Sacro Cuore - Don
Calabria,
Negrar (VR)

Nicla La Verde

A.S.S.T. Fatebenefratelli Sacco,
Milano

Giuseppe Lombardi

Istituto Oncologico Veneto,
Padova

Sara Lonardi

Istituto Oncologico Veneto,
Padova

Giuseppe Lo Russo

Fondazione IRCCS Istituto Nazionale
dei Tumori di Milano,
Milano

Vito Lorusso

Istituto Tumori Giovanni Paolo II,
Bari

Claudio Luchini

Università degli Studi,
Verona

Antonio Marchetti

Università G. D'Annunzio,
Chieti

Paolo Marchetti

Azienda Ospedaliero-Universitaria
Sant'Andrea,
Roma

Marco Merlano

A. O. S. Croce e Carle,
Cuneo

Enrico Mini

A.O.U. Careggi,
Firenze

Giorgio Minotti

Università Campus Bio-Medico,
Roma

Filippo Montemurro

Istituto di Candiolo IRCCS,
Candiolo (To)

Federica Morano

Fondazione IRCCS Istituto Nazionale
Tumori,
Milano

Emanuele Neri

Istituto Dipartimento di Ricerca
Traslationale, Università di Pisa

Fabrizio Nicolis

Presidente Fondazione Aiom,
IRCCS Ospedale Sacro Cuore - Don
Calabria,
Negrar (VR)

Giuseppe Procopio

Fondazione IRCCS Istituto Nazionale
dei Tumori,
Milano

Paola Queirolo

A.O.U. S. Martino,
Genova

Luigi Ruco

Università La Sapienza,
Roma

Antonio Russo

A.O.U. Policlinico P. Giaccone,
Palermo

Stefano Severi

IRST-IRCCS, Meldola (FC)

Nicola Silvestris

Ospedale Giovanni Paolo II,
Bari

Valentina Sini

ASL Roma1 UOSD Centro Oncologico,
SS-NRM,
Roma

Pierfrancesco Tassone

Università Magna Graecia,
Catanzaro

Giuseppe Toffoli

C.R.O.,
Aviano (PN)

Stefania Tommasi

IRCCS-OSPEDALE ONCOLOGICO,
Bari

Giancarlo Troncone

Università degli Studi "Federico II",
Napoli

Elena Vigliar

Università Federico II,
Napoli

Vittorina Zagonel

Istituto Oncologico Veneto IRCCS,
Padova



SESSION I A CHANGING WORLD...

Moderators: *F. Cognetti, L. Ruco*

10.00 From histology to the molecular profile:
integrated diagnostic approach to neoplasms

C. Luchini


Response Predictive factors to immunotherapeutic drugs
from PDL-1 to Tumor Mutational Burden:

- 10.15 the pathologist *G. Troncone, E. Vigliar*
- 10.25 the pharmacologist *R. Danesi*

10.35 The tumor microenvironment and new drugs

F. Cognetti

10.50 Discussion



SESSION II UNANSWERED QUERIES

Moderators: *M. Merlano, E. Mini*

11.00 “Driver” mutation and “Passenger” mutation:
what is the clinical meaning?

S. Tommasi

11.15 The new immune-related response criteria (iRECIST):
are always adequate

G. Lo Russo

11.30 The design and conduct of clinical trials in the era of precision oncology:
what is changing?

E. De Luca, M. Di Maio

12.00 Discussion

SESSION III BRCA MUTATED OVARIAN CARCINOMA

Moderators: *G. De Rosa, N. La Verde*

12.00 AIOM-SIGU-SIBIOP-SIAPEC-IAP 2019 recommendations

L. Cortesi

12.15 The use of new genomic technologies in BRCA mutated ovarian
cancer patients: what information?

E. Capoluongo

12.30 Germinal pharmacogenetics
G. Toffoli

12.45 Discussion

13.30 Working Lunch

SESSION IV ONCOGENE-ADDICTED NSCLC

Moderators: *F. Grossi, A. Inno*

14.30 The development of resistances:
clinical impact and therapeutic strategies
M. Del Re

14.45 Liquid biopsy recommendations
AIOM -SIAPEC-IAP-SIF-SIBioC
A. Russo

15.00 Criteria of response during therapies in TKI:
clinical or molecular criteria?
E. Bria

15.15 The new targets: ROS1, MEK, NTRK
A. Del Monte

15.30 Discussion

SESSION V COLORECTAL CARCINOMA



Moderators: *C. Carnaghi, V. Zagonel*

16.00 Definition, effect, clinical course, therapies
S. Lonardi

16.15 New therapies and scientific evidence
F. Morano

16.30 Position of regulatory bodies: FDA, EMA, AIFA
R. Bordonaro

16.45 Discussion






SESSION VI MALIGNANT MELANOMA, CEREBRAL AND UROLOGICAL NEOPLASMS

Moderators: *G. Carteni, P. Queirolo*

- 17.15 **2019: adjuvant treatment of malignant melanoma**
V. Chiarion Sileni
- 17.30 **New targets in brain neoplasms**
G. Lombardi
- 17.45 **BRCA2 and prostate carcinoma**
G. Procopio
- 18.00 **Urological malignancies and immunotherapy: which targets?**
L. Incorvaia
- 18.15 **Discussion**
- 18.30 **Conclusion of works**




SESSION VII BREAST CANCERModerators: *S. Cinieri, S. Gori*

- 8.30 PI3KA mutations and ER mutations:
what impact on the outcome of breast cancer patients?
- the pharmacologist *G. Minotti*
 - the oncologist *A. Fabi*
- 9.15 BRCA mutated metastatic breast cancer:
What is the role of PARP-I?
V. Guarneri
- 9.30 Immunotherapy in breast cancer: what evidence?
V. Sini
- 9.45 Discussion

Sessione VIII NEW FRONTIERSModerators: *V. Lorusso, S. Severi*

- 10.00 Radio receptor therapy
S. Severi
- 10.20 Radiomics
E. Neri
- 10.40 Discussion
- 11.00 Coffee Break





SESSION IX THE AGNOSTIC-TISSUE PRECISION MEDICINE: AN EMERGING APPROACH


Moderators: *N. Silvestris, P. Tassone*

- 11.30 **Rational and therapeutic bases**
P. Marchetti
- 11.45 **New targets: are they always clinically useful?**
F. Montemurro
- 12.00 **Ongoing clinical studies**
P. Marchetti
- 12.15 **Patients' requests**
F. Nicolis
- 12.30 **Reading: The importance of interdisciplinary working groups in the age of precision oncology. The Molecular Tumor Board (MTB): from clinical indications to regulatory contexts**
P. Conte
- 12.50 **Discussion**
- 13.15 **Conclusions**



PARALLEL SESSION AIOM FOUNDATION MEETS PATIENTS AND CITIZENSModerator: *F. Nicolis*

- 09.00 Precision oncology: characterize the tumor to decide on the appropriate treatment
A. Marchetti
- 09.15 Molecular target therapies in oncology: what results?
A. Russo
- 09.30 Immunotherapy in oncology: results and perspectives
A. Fabi
- 09.45 Discussion
- Patients ask ... oncologists answer
- 11.30 Conclusions





AIOM
Via Enrico Nöe 23 - 20133 Milano
Tel. 0270630279 - Fax 022360018
aiom.segretario@aiom.it
www.aiom.it



FONDAZIONE AIOM
Via Enrico Nöe 23 - 20133 Milano
Tel. 0226683335 - Fax 0259610555
fondazioneaiom@fondazioneaiom.it
www.fondazioneaiom.it




Servizi
Provider ECM
ISO 9001

SEGRETERIA ORGANIZZATIVA
AIOM Servizi Srl

Sede di Milano
Via Enrico Nöe 23 - 20133 Milano
Tel. 0226683129 - Fax 0259610555
info@aiomservizi.it

Sede di Roma
Via Domenico Cimarosa 18 - 00198 Roma
Tel. 068553259 - Fax 068553221
info@aiomservizi.it



GRAZIE ALLA SPONSORIZZAZIONE NON CONDIZIONANTE DI:

